Sanofi wins SCOTUS stay of Lantus patent dispute
13-02-2020
Sanofi takes on Mylan over diabetes injection
25-10-2017
Sanofi sues Merck over Lantus patents
21-09-2016
bee32 / iStockphoto.com
The US Patent Trial and Appeal Board (PTAB) has instituted inter partes reviews (IPRs) of two patents owned by Sanofi covering Lantus (insulin glargine injection).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan, Patent Trial and Appeal Board, PTAB, inter partes review, patents, diabetes, Sanofi, Lantus
